COMMON STOCK (Details)
|
|
|
|
|
|
|
|
|
1 Months Ended |
12 Months Ended |
33 Months Ended |
|
|
|
|
|
|
|
Dec. 23, 2025
USD ($)
D
$ / shares
shares
|
Sep. 16, 2025
USD ($)
$ / shares
shares
|
Apr. 04, 2025
USD ($)
shares
|
Mar. 11, 2025
USD ($)
|
Jul. 01, 2024
USD ($)
$ / shares
shares
|
Jan. 26, 2024
USD ($)
$ / shares
shares
|
Jan. 24, 2024
USD ($)
$ / shares
shares
|
Mar. 28, 2023
USD ($)
$ / shares
|
Aug. 31, 2024
USD ($)
shares
|
Jul. 31, 2024
USD ($)
$ / shares
shares
|
Jan. 31, 2024
$ / shares
shares
|
Dec. 31, 2025
USD ($)
$ / shares
shares
|
Dec. 31, 2024
USD ($)
$ / shares
shares
|
Dec. 31, 2025
USD ($)
$ / shares
shares
|
Mar. 30, 2026
USD ($)
|
Sep. 30, 2025
$ / shares
|
Mar. 31, 2025
$ / shares
shares
|
Mar. 12, 2025
USD ($)
$ / shares
|
Aug. 02, 2024
USD ($)
|
Aug. 01, 2024
$ / shares
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, par value | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
$ 0.001
|
$ 0.001
|
|
|
|
|
|
|
| Gross proceeds |
|
|
|
$ 2,703,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Legal fees |
|
|
|
|
|
|
|
|
|
|
|
$ 85,000
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of common stock from exercise of warrants |
|
|
|
|
|
|
|
|
|
|
|
112,000
|
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
|
|
|
|
|
|
|
|
|
|
5,607,000
|
$ (1,346,000)
|
|
|
|
|
|
|
|
| Fair values of the Warrants |
|
|
|
|
|
|
|
|
|
|
|
$ 97,000
|
$ 61,000
|
$ 97,000
|
|
|
|
|
|
|
| Warrants issued | shares |
|
|
|
|
|
|
|
|
|
|
|
21,235,745
|
4,475,068
|
21,235,745
|
|
|
|
|
|
|
| Offset of additional paid in capital |
|
|
|
|
|
|
|
|
|
|
|
|
$ 277,000
|
|
|
|
|
|
|
|
| Securities Purchase Agreements |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
|
|
|
|
|
|
9,733
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of common stock |
|
|
|
|
|
|
|
|
$ 11,000
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant Inducement Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.25
|
| Proceeds from warrants issued |
|
|
|
|
|
|
|
|
|
$ 1,862,000
|
|
|
|
|
|
|
|
|
|
|
| Warrants modification value |
|
|
|
|
|
|
|
|
|
$ 1,323,000
|
|
|
|
|
|
|
|
|
|
|
| March 2025 Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of warrants |
|
|
|
|
|
|
|
|
|
|
|
$ 6,777,000
|
|
$ 6,777,000
|
|
|
|
$ 1,477,000
|
|
|
| 2022 Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares of common stock called by warrants | shares |
|
|
|
|
|
366,664
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
$ 13.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
|
|
|
|
$ 106,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 Amended Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
$ 4.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
|
|
|
|
$ 490,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| August 2022 Warrants | Warrant Inducement Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 4.13
|
|
|
|
|
|
|
|
|
|
|
| August 2022 Warrants | Common Stock | Warrant Inducement Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares of common stock called by warrants | shares |
|
|
|
|
|
|
|
|
|
311,111
|
|
|
|
|
|
|
|
|
|
|
| January 2024 Warrants | Warrant Inducement Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 4.13
|
|
|
|
|
|
|
|
|
|
|
| January 2024 Warrants | Common Stock | Warrant Inducement Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares of common stock called by warrants | shares |
|
|
|
|
|
|
|
|
|
1,400,000
|
|
|
|
|
|
|
|
|
|
|
| August 2024 Warrants | Common Stock | Warrant Inducement Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares of common stock called by warrants | shares |
|
|
|
|
|
|
|
|
|
2,566,667
|
|
|
|
|
|
|
|
|
|
|
| Warrants and rights outstanding, term |
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
| March 2025 Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.5
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.35
|
$ 0.25
|
$ 0.25
|
|
|
| Warrants and rights outstanding, term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
| March 2025 Warrants | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.5
|
|
|
|
| Amended March 2025 Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.35
|
|
|
|
|
| Maximum | March 2025 Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,298,177
|
|
|
|
| LPC Purchase Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, par value | $ / shares |
|
|
|
|
|
|
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum aggregate offering price |
|
|
|
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 Equity Line of Credit Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
|
|
|
|
|
|
|
|
|
0
|
949,574
|
1,310,517
|
|
|
|
|
|
|
| Gross proceeds |
|
|
|
|
|
|
|
|
|
|
|
$ 3,078,000
|
$ 1,900,000
|
|
|
|
|
|
|
|
| Stock issuance expenses |
|
|
|
|
|
|
|
|
|
|
|
326,000
|
|
|
|
|
|
|
|
|
| Legal fees |
|
|
|
|
|
|
|
|
|
|
|
0
|
$ 249,000
|
|
|
|
|
|
|
|
| 2023 Equity Line of Credit Agreement | Maximum | Lincoln Park Capital Fund |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Remaining value of shares to be sold under the agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,700,000
|
|
|
|
|
|
| 2024 Registered Direct Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, par value | $ / shares |
|
|
|
|
|
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
|
|
|
|
1,371,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds |
|
|
|
|
|
|
$ 5,563,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued price per share | $ / shares |
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance costs |
|
|
|
|
|
|
$ 733,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 Registered Direct Offering | Warrant Inducement Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercised | shares |
|
|
|
|
|
|
|
|
|
|
1,400,000
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 1.25
|
|
|
|
|
|
|
|
|
|
| 2024 Registered Direct Offering | Pre Funded Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares of common stock called by warrants | shares |
|
|
|
|
|
|
200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant restriction, threshold common stock held, percent |
|
|
|
|
|
|
9.99%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of common stock from exercise of warrants |
|
|
|
|
|
|
$ 20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 Registered Direct Offering | Purchase Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares of common stock called by warrants | shares |
|
|
|
|
|
|
1,571,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant price | $ / shares |
|
|
|
|
|
|
$ 0.125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 4.13
|
|
|
|
|
|
|
|
|
|
| 2024 Registered Direct Offering | Investors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
|
|
|
|
1,368,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price | $ / shares |
|
|
|
|
|
|
$ 3.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 Registered Direct Offering | Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
|
|
|
|
2,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued price per share | $ / shares |
|
|
|
|
|
|
$ 4.255
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 Registered Direct Offering | Chief Executive Officer | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price | $ / shares |
|
|
|
|
|
|
$ 4.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 Registered Direct Offering | Alliance Global Partners |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent cash fee paid |
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent cash fee |
|
|
|
|
|
|
3.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Legal fees |
|
|
|
|
|
|
$ 75,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-accountable expense allowance |
|
|
|
|
|
|
$ 30,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 Private Placement Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
|
|
1,248,529
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds from issuance of private placement |
|
|
|
|
$ 1,909,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance costs |
|
|
|
|
$ 72,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 Private Placement Offering | July 2024 Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued price per share | $ / shares |
|
|
|
|
$ 1.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
|
|
|
$ 2.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| At The Market Offering Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total gross proceeds |
|
|
|
|
|
|
|
|
|
|
|
4,388,000
|
|
|
|
|
|
|
|
|
| Remaining value of shares to be sold under the agreement |
|
|
|
|
|
|
|
|
|
|
|
62,000
|
|
$ 62,000
|
|
|
|
|
|
|
| Issuance costs |
|
|
|
|
|
|
|
|
|
|
|
$ 147,000
|
|
|
|
|
|
|
|
|
| At The Market Offering Agreement | HC Wainwright Co |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
|
|
|
|
|
|
|
|
|
12,277,441
|
1,073,050
|
|
|
|
|
|
|
|
| Gross proceeds |
|
|
|
|
|
|
|
|
|
|
|
$ 3,484,000
|
$ 903,000
|
|
|
|
|
|
|
|
| Stock issuance expenses |
|
|
|
|
|
|
|
|
|
|
|
|
$ 240,000
|
|
|
|
|
|
|
|
| Aggregate maximum sale price of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,450,000
|
|
| Commission rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00%
|
|
| 2025 Equity Line Of Credit Agreement | Lincoln Park Capital Fund |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum aggregate offering price |
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase agreement term |
24 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
824,493
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of common stock |
|
|
|
|
|
|
|
|
|
|
|
412,000
|
|
|
|
|
|
|
|
|
| Legal fees |
|
|
|
|
|
|
|
|
|
|
|
$ 28,000
|
|
|
|
|
|
|
|
|
| Maximum number of shares per purchase |
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Threshold percentage of regular purchase price |
95.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of lowest common stock | D |
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Threshold trading days | D |
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accelerated purchase, Share purchase ratio |
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accelerated purchase, Percentage of trading volume |
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accelerated purchase price, Threshold percentage |
95.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notice period for termination of agreement |
1 day
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Beneficial ownership percentage |
4.99%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Beneficial ownership percentage, Threshold |
9.99%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notice period for increase of beneficial ownership |
61 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Referral fees |
$ 84,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Transaction cost |
$ 412,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2025 Equity Line Of Credit Agreement | Lincoln Park Capital Fund | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
|
|
|
|
|
|
|
|
|
824,493
|
|
|
|
|
|
|
|
|
| 2025 Equity Line Of Credit Agreement | Lincoln Park Capital Fund | Share price range greater than $0.10 per share but below $0.50 per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price | $ / shares |
$ 0.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum number of shares per purchase | shares |
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2025 Equity Line Of Credit Agreement | Lincoln Park Capital Fund | Share price range from $0.50 per share and greater but below $0.75 per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price | $ / shares |
$ 0.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum number of shares per purchase | shares |
75,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2025 Equity Line Of Credit Agreement | Lincoln Park Capital Fund | Share price range greater than $0.75 per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price | $ / shares |
$ 0.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum number of shares per purchase | shares |
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2025 Equity Purchase Agreement | Triton Funds L.P. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
354,988
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds |
|
|
$ 25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of common stock |
|
|
|
|
|
|
|
|
|
|
|
$ 25,000
|
|
|
|
|
|
|
|
|
| Sale of stock |
|
|
2,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Transaction cost |
|
|
$ 214,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2025 Equity Purchase Agreement | Triton Funds L.P. | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
|
|
|
|
|
|
|
|
|
|
354,988
|
|
|
|
|
|
|
|
|
| Issuance of common stock |
|
|
|
|
|
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
|
|
|
| 2025 Private Placement Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued under equity line of credit agreement, shares | shares |
|
6,550,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds from issuance of private placement |
|
$ 2,950,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance costs |
|
$ 140,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2025 Private Placement Offering | September 2025 Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued price per share | $ / shares |
|
$ 0.45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise Price per Share | $ / shares |
|
$ 0.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|